Cresco Labs Inc. (CRLBF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cresco Labs Inc. (CRLBF) trades at $0.78 with AI Score 45/100 (Grade C). Cresco Labs Inc. is a leading cannabis company in the U. S. Market cap: $275.45M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CRLBF: CRLBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CRLBF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CRLBF: the 1 perspectives are evenly split.
How is this calculated? →Cresco Labs Inc. (CRLBF) Healthcare & Pipeline Overview
Cresco Labs Inc. stands out in the cannabis sector with a robust portfolio of brands and a multi-state retail presence, catering to both medical and recreational markets while navigating the complexities of regulatory landscapes.
What Is the Investment Thesis for CRLBF?
Cresco Labs Inc. is positioned for growth in the expanding cannabis market, which is projected to reach $41.5 billion by 2025. The company's diverse brand portfolio, including Cresco, High Supply, and Mindy's Edibles, allows it to cater to a wide range of consumer preferences. With a gross margin of 48.6%, Cresco Labs demonstrates strong operational efficiency compared to industry peers. However, the company faces risks associated with its OTC trading status, which may limit liquidity and transparency. Regulatory changes in the cannabis industry could impact market dynamics, making it crucial for Cresco Labs to adapt quickly to maintain its competitive edge. The company's ability to expand its retail footprint and enhance brand recognition will be key drivers of future revenue growth.
Based on FMP financials and quantitative analysis
CRLBF Key Highlights
- Market Cap of $275.45M reflects the company's current valuation in the cannabis sector.
- Gross Margin of 48.6% indicates strong operational efficiency compared to industry standards.
- Profit Margin of -21.3% highlights challenges in achieving profitability amid competitive pressures.
- Beta of 1.71 suggests higher volatility compared to the overall market, indicating potential risk.
- No dividend yield as the company reinvests earnings to support growth initiatives.
Who Are CRLBF's Competitors?
CRLBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CURLF Curaleaf Holdings, Inc. | $9.60 | -6.20% | $2.54B | 53 |
| GTBIF Green Thumb Industries Inc. | $7.16 | -5.79% | $1.66B | 57 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CRLBF's Key Strengths?
- Diverse brand portfolio catering to various consumer segments.
- Strong operational capabilities with significant cultivation and production capacity.
- Established retail network enhances market presence and consumer access.
What Are CRLBF's Weaknesses?
- Negative profit margin indicating challenges in achieving profitability.
- OTC trading status may limit visibility and liquidity compared to major exchanges.
- Dependence on regulatory environment which can impact operations.
What Could Drive CRLBF Stock Higher?
- Expansion into new states as cannabis legalization progresses.
- Development of new product lines to meet consumer demand.
- Strategic partnerships to enhance distribution capabilities.
- Anticipated regulatory changes that could benefit market access.
- Continued investment in marketing and brand awareness initiatives.
What Are the Key Risks for CRLBF?
- Financial-distress signal — its Altman Z-Score of -0.76 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-35.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory changes that could impact market access and operations.
- Intense competition from established cannabis operators.
- Market volatility affecting cannabis pricing and consumer demand.
- Challenges related to liquidity due to OTC trading status.
What Are the Growth Opportunities for CRLBF?
- Market Expansion: Cresco Labs has the opportunity to expand its retail footprint beyond its current 48 dispensaries. As more states legalize cannabis, the company can capitalize on new markets, potentially increasing its revenue significantly. The U.S. cannabis market is expected to grow to $41.5 billion by 2025, providing a substantial opportunity for Cresco Labs to enhance its market share.
- Product Diversification: With a strong portfolio of brands, Cresco Labs can continue to innovate and introduce new products tailored to consumer preferences. The demand for cannabis-infused edibles and wellness products is on the rise, and Cresco's existing brands like Mindy's Edibles and Remedi position the company well to capture this growing segment.
- Strategic Partnerships: Forming strategic partnerships with other companies in the cannabis space can enhance Cresco Labs' distribution capabilities and brand reach. Collaborations with established brands or retailers can help the company penetrate new markets more effectively and increase its overall sales.
- Regulatory Advancement: As legislation around cannabis continues to evolve, Cresco Labs could benefit from favorable regulatory changes that expand market access. The potential for federal legalization or more lenient state regulations could significantly enhance the company's growth prospects and operational capabilities.
- Increased Consumer Acceptance: Growing public acceptance of cannabis products, particularly for medical use, presents an opportunity for Cresco Labs to increase its customer base. As awareness and education around cannabis benefits improve, the company can leverage its established brand reputation to attract new consumers.
What Opportunities Does CRLBF Have?
- Expansion into new markets as states legalize cannabis.
- Growing demand for cannabis-infused edibles and wellness products.
- Potential for strategic partnerships to enhance distribution and brand reach.
What Threats Does CRLBF Face?
- Intense competition from established cannabis operators.
- Regulatory changes that could impact market access and operations.
- Market volatility affecting cannabis pricing and consumer demand.
What Are CRLBF's Competitive Advantages?
- Established brand portfolio with recognized names in the cannabis market.
- Multi-state operational presence providing competitive advantages in distribution.
- Strong compliance and regulatory expertise in navigating the cannabis landscape.
- Diverse product offerings catering to a wide range of consumer preferences.
- Significant retail network enhancing consumer access to products.
What Does CRLBF Do?
Cresco Labs Inc., established in 2013 and headquartered in Chicago, Illinois, is a prominent player in the cannabis industry, focusing on the cultivation, production, and distribution of medical and recreational cannabis products across the United States. The company has developed a comprehensive portfolio of brands that cater to diverse consumer needs. Its flagship brand, Cresco, offers a wide range of products including flowers, vape pens, live resins, disposable pens, and extracts. The High Supply label provides an extensive selection of cannabis products including vape cartridges, flower, and pre-rolls. For those seeking vapes and gummies, the Good News brand is available, while Wonder Wellness Co. specializes in wellness-focused vapes and edibles. The Remedi brand offers tinctures, capsules, and salves, focusing on wellness applications, and the Reserve brand provides a general range of cannabis products. Premium cannabis flowers are marketed under the FloraCal brand, while Mindy's Edibles features a variety of cannabis-infused chocolates and gummies. Cresco Labs also holds a license for the Kiva brand, known for its high-quality cannabis-infused edibles. As of January 27, 2022, Cresco Labs operated 48 owned dispensaries, showcasing its extensive retail network. The company's strategic focus on brand diversification and multi-state operations positions it well to capitalize on the growing demand for cannabis products in the U.S.
What Products and Services Does CRLBF Offer?
- Cultivate and produce medical and recreational cannabis products.
- Operate a diverse portfolio of cannabis brands catering to various consumer needs.
- Manage a network of dispensaries for direct retail sales.
- Develop and market cannabis-infused edibles and wellness products.
- Engage in wholesale distribution of cannabis products to other retailers.
- Focus on compliance with state and federal regulations in the cannabis industry.
How Does CRLBF Make Money?
- Generate revenue through the sale of cannabis products in owned dispensaries.
- Wholesale distribution of cannabis products to other retailers and dispensaries.
- Leverage brand portfolio to capture a wide range of consumer preferences.
- Focus on product innovation to meet evolving market demands.
- Utilize economies of scale in cultivation and production to enhance profitability.
What Industry Does CRLBF Operate In?
The cannabis industry is experiencing rapid growth, driven by increasing legalization and consumer acceptance of cannabis products for both medical and recreational use. The U.S. cannabis market is projected to grow significantly, with estimates suggesting it could reach $41.5 billion by 2025. Cresco Labs operates in a competitive landscape with several key players, including Curaleaf and Trulieve, which are also expanding their market presence. The evolving regulatory environment presents both opportunities and challenges, as companies must navigate varying state laws and compliance requirements.
Who Are CRLBF's Key Customers?
- Medical cannabis patients seeking therapeutic products.
- Recreational consumers looking for various cannabis formulations.
- Retail dispensaries purchasing products for resale.
- Health-conscious consumers interested in wellness-focused cannabis products.
- Edible consumers seeking cannabis-infused snacks and treats.
ROE -35%Key Financial Metrics
Return on equity for Cresco Labs Inc. stands at -35.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.51 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -45.2%, the inverse of the P/E and a quick read on earnings relative to price.
Cresco Labs Inc. (CRLBF) Valuation Context
Valued at $275.45M, CRLBF is classified as a micro-cap stock. Relative to its peer group, CRLBF's quantitative score of 45/100 is below the peer average of 63/100.
Company Profile
Cresco Labs Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Chicago, US. The company is led by CEO Charles Bachtell. CRLBF has traded publicly since 2018.
F-Score 2/9Financial Health
Cresco Labs Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.76 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Cresco Labs Inc. revenue of about $654.4M for fiscal 2026, with EPS near $-0.08. The estimate reflects 5 contributing analysts.
CRLBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Cresco's recent insider buying suggests confidence from those who know the company best, signaling potential undervaluation.
- Community sentiment shows increasing optimism about Cresco's expansion into key markets.
- The overall market perception is shifting positively as cannabis legalization gains momentum in several states.
- Bullish community members highlight Cresco's strategic acquisitions as a pathway to increased market share.
Bear Case
- Recent insider selling, while not always indicative of a negative outlook, could raise concerns about short-term performance.
- Bearish community views point to potential regulatory hurdles hindering Cresco's growth in certain states.
- Market perception is wary of potential oversupply issues in the cannabis industry affecting Cresco's profitability.
- Some community members express concerns about Cresco's debt levels and their impact on long-term financial stability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CRLBF Latest News
-
Cannabis Operator Cresco Down 28.5% YTD: How to Play the Stock?
zacks.com · Jun 11, 2026
-
Cresco Labs Closes US$50 Million Revolving Credit Facility with Needham Bank
businesswire.com · Jun 8, 2026
-
Cresco Labs Marks Historic Step Forward with Medical Cannabis Facility DEA Registration
businesswire.com · May 27, 2026
-
Cannabis Technology Strategic Business Research Report 2026: A $28.3 Billion Market by 2032 from $5.6 Billion in 2025 Featuring Aeropay, C3 Industries, Confident Cannabis, Cresco Labs, Dutchie
Yahoo! Finance: CRLBF News · May 18, 2026
CRLBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CRLBF.
Price Targets
Wall Street price target analysis for CRLBF.
CRLBF MoonshotScore
What does this score mean?
The MoonshotScore rates CRLBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Cannabis Operator Cresco Down 28.5% YTD: How to Play the Stock?
Cresco Labs Closes US$50 Million Revolving Credit Facility with Needham Bank
Cresco Labs Marks Historic Step Forward with Medical Cannabis Facility DEA Registration
Cannabis Technology Strategic Business Research Report 2026: A $28.3 Billion Market by 2032 from $5.6 Billion in 2025 Featuring Aeropay, C3 Industries, Confident Cannabis, Cresco Labs, Dutchie
Leadership: Charles Bachtell
CEO
Charles Bachtell co-founded Cresco Labs in 2013 and has been instrumental in its growth and development. He holds a degree in business from the University of Illinois and has extensive experience in the cannabis industry, focusing on compliance and operational excellence. Prior to Cresco, Bachtell worked in various roles that honed his skills in business strategy and management.
Track Record: Under Charles Bachtell's leadership, Cresco Labs has expanded its retail network significantly and developed a diverse brand portfolio. His strategic decisions have positioned the company as a leader in the cannabis industry, navigating the complexities of regulations and market dynamics effectively.
CRLBF OTC Market Information
The OTC Other tier includes companies that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier may have lower liquidity and less stringent reporting standards, which can affect investor confidence and market perception.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower liquidity compared to stocks listed on major exchanges.
- Potential for less rigorous financial reporting and oversight.
- Increased volatility due to limited market participation.
- Verify the company's financial health through available reports.
- Assess the regulatory environment affecting the cannabis industry.
- Monitor competitive landscape and market trends.
- Evaluate management's track record and strategic vision.
- Examine the company's growth strategies and market expansion plans.
- Established brand presence in the cannabis market.
- Regulatory compliance in multiple states.
- Transparent communication of business operations and financials.
Cresco Labs Inc. Healthcare Stock: Key Questions Answered
What does Cresco Labs Inc. do?
Cresco Labs Inc. is a cannabis company that cultivates, produces, and sells both medical and recreational cannabis products throughout the United States. The company operates a diverse portfolio of brands, including Cresco, High Supply, and Mindy's Edibles, offering a wide range of cannabis formulations and products to meet various consumer needs.
What are the main risks for CRLBF?
Cresco Labs faces several risks, including regulatory changes that could impact its market access and operations. The company operates in a highly competitive landscape, which may affect its pricing and market share. Additionally, its OTC trading status presents liquidity challenges, potentially leading to increased volatility in its stock price.
How does Cresco Labs Inc. navigate regulatory approval processes?
Cresco Labs has established a robust compliance framework to navigate the complex regulatory landscape of the cannabis industry. The company works closely with state regulators to ensure adherence to all legal requirements and actively participates in advocacy efforts to shape favorable regulations. This proactive approach helps Cresco maintain its operational licenses and expand its market presence.
What are the key factors to evaluate for CRLBF?
Cresco Labs Inc. (CRLBF) holds an AI score of 45/100 (low). Not financial advice.
How frequently does CRLBF data refresh on this page?
CRLBF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CRLBF's recent stock price performance?
Cresco Labs Inc. (CRLBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse brand portfolio catering to various consumer segments. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CRLBF overvalued or undervalued right now?
Valuing Cresco Labs Inc. (CRLBF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CRLBF?
Before investing in Cresco Labs Inc. (CRLBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information and may be subject to change.